Table 4.

Univariate analyses of potential effect modifiers, HIV-positive womena

Transition health stage
Initial health stageTotalnHR (95% CI)PnHR (95% CI)P
HPVHSIL
Normal
 CD4+ count < 20057291.09 (0.72–1.67)0.6842.86 (0.95–8.58)0.06
 CD4+ count ≥ 200423260ref.13ref.
 HPV - 16/1827240.97 (0.64–1.49)0.9034.62 (1.10–19.42)0.04
 HPV - Other206189ref.5ref.
 HPV - Multiple Types71641.07 (0.79–1.43)0.6731.37 (0.33–5.69)0.66
 HPV - Single Type162149ref.5ref.
 Age ≤ 2569471.56 (1.14–2.14)0.006010.41 (0.05–3.10)0.39
 Age > 25436249ref.16ref.
 HIV-13162051.85 (1.38–2.49)<0.000180.48 (0.19–1.21)0.12
 HIV-215574ref.9ref.
NormalHSIL
HPV
 CD4+ count < 200116380.57 (0.39–0.83)0.003231.83 (1.07–3.14)0.0282
 CD4+ count ≥ 200477261ref.58ref.
 HPV - 16/18176290.35 (0.23–0.54)<0.0001322.20 (1.34–3.62)0.0018
 HPV - Other473186ref.42ref.
 HPV - Multiple Types327660.34 (0.25–0.47)<0.0001512.33 (1.40–3.88)0.0011
 HPV - Single Type322149ref.23ref.
 Age ≤ 2587461.29 (0.89–1.87)0.17131.14 (0.57–2.27)0.72
 Age > 25545261ref.70ref.
 HIV-14251920.83 (0.64–1.08)0.17631.69 (0.94–3.03)0.08
 HIV-216394ref.16ref.
  • Abbreviations: Normal, HPV-negative; HPV, HPV-positive with one or more type in the absence of HSIL; HSIL, HPV-positive with one or more type with the presence of HSIL; Incident, stage differed from the preceding visit; Prevalent, baseline visit or stage was the same as the preceding visit.

  • aNote that transition numbers (by row) do not sum to total as some women remained in the same state for the duration of follow-up. HPV-type specific analyses for transitions from Normal (the initial state) were conducted based on the type acquired, whereas analyses of transitions from HPV (the initial state) were conducted on the basis of what type women had while HPV-positive.